Anti-obesity Drugs Market Report 2024-2034

Anti-obesity Drugs Market Report 2024-2034

The Anti-obesity Drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increased Prevalence of Obesity

Over the past few decades, obesity rates have risen dramatically across all age groups and demographics, fuelled by a combination of genetic, environmental, socioeconomic, and cultural factors. The World Obesity Federation estimated that by 2020 around 770 million adults globally were affected by obesity, and that figure is anticipated to exceed one billion by 2030. Changes in dietary habits, sedentary lifestyles, urbanization, and globalization have contributed to the widespread adoption of unhealthy eating patterns and reduced physical activity levels, leading to excess weight gain and obesity-related health complications. Moreover, obesity is not only a standalone health condition but also a major risk factor for numerous chronic diseases, including type 2 diabetes, cardiovascular diseases, certain cancers, and musculoskeletal disorders, further exacerbating its impact on population health. The consequences of obesity extend beyond individual health outcomes to encompass societal and economic burdens, including increased healthcare costs, lost productivity, and diminished quality of life. Addressing the multifaceted drivers of obesity requires a comprehensive and multi-sectoral approach that encompasses policy interventions, community-based initiatives, education campaigns, and healthcare strategies aimed at promoting healthy lifestyles, improving access to nutritious foods, and creating supportive environments for physical activity. By tackling the root causes of obesity and implementing effective prevention and treatment measures, stakeholders can mitigate the escalating obesity epidemic and mitigate its far-reaching consequences on global health and well-being.

Rising Healthcare Expenditure

As obesity rates continue to climb globally, healthcare systems are increasingly allocating resources towards interventions aimed at combating this epidemic. This heightened expenditure encompasses various aspects, including research and development efforts to innovate new and more effective anti-obesity drugs, healthcare provider education and training on obesity management strategies, as well as patient outreach and support programs. Additionally, the economic burden of obesity-related health complications, such as diabetes, cardiovascular diseases, and certain cancers, further underscores the necessity of investing in preventive and therapeutic measures to mitigate these downstream health costs. Furthermore, as healthcare systems transition towards value-based care models that prioritize preventive interventions and chronic disease management, there is a growing emphasis on the role of pharmacotherapy in comprehensive obesity treatment plans. While the upfront costs of anti-obesity drugs may seem significant, they are often outweighed by the potential long-term benefits of improved health outcomes and reduced healthcare expenditures associated with obesity-related comorbidities. Overall, the rising healthcare expenditure in the anti-obesity drugs market reflects a strategic investment in addressing a pressing public health issue and underscores the importance of prioritizing obesity management within healthcare budgets to mitigate the broader societal and economic impacts of this epidemic.

What Questions Should You Ask before Buying a Market Research Report?

• How is the Anti-obesity Drugs Market evolving?
• What is driving and restraining the Anti-obesity Drugs Market?
• How will each Anti-obesity Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each Anti-obesity Drugs submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading Anti-obesity Drugs Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Anti-obesity Drugs projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of Anti-obesity Drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Anti-obesity Drugs Market?
• Where is the Anti-obesity Drugs Market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Anti-obesity Drugs Market today, and over the next 10 years:

• Our 310-page report provides 134 tables and 191 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Anti-obesity Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising anti-obesity drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Drug Type

• Prescription
• OTC

Mechanism of Action

• Glucagon like Peptide GLP-1 Agonists
• Gastric inhibitory Polypeptide Receptor (GIPR) Antagonist
• Amylin Receptor Agonist
• Lipase Inhibitors
• Serotonin and Norepinephrine Reuptake Inhibitor (SNRI)
• Others

Route of Administration

• Oral
• Intravenous
• Subcutaneous

Distribution channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Poland
• Belgium
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Taiwan
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Anti-obesity Drugs Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

• Arena Pharmaceuticals Ltd.
• Bayer AG
• Boehringer Ingelheim International GmbH
• Carmot Therapeutics, Inc.
• CHEPLAPHARM Arzneimittel GmbH
• CohBar, Inc.
• Curaxx Pharmaceuticals LLC
• Eisai Co., Ltd.
• Eli Lilly and Co
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline Plc
• Hanmi Pharm Co., Ltd.
• Merck & Co., Inc.
• Novo Nordisk A/S
• Pfizer Inc.
• Rhythm Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• VIVUS LLC
• Zydus Lifesciences

Overall world revenue for Anti-obesity Drugs Market, 2024 to 2034 in terms of value the market will surpass US$78,000 million in 2034, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Anti-obesity Drugs Market, 2024 to 2034 report help you?

In summary, our 310-page report provides you with the following knowledge:

• Revenue forecasts to 2034 for Anti-obesity Drugs Market 2024 to 2034, with forecasts for drug type, Mechanism of action, route of administration, and distribution channel, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 27 key national markets – See forecasts for the Anti-obesity Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 17 of the major companies involved in the Anti-obesity Drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Anti-obesity Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher..

The publisher is using a password system to access single user and team licenses. Single user (non-printable) and team licenses expire after 12 month period. In the case of team license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.